Yea that would be a stupid move on TRXC's part unless it was for pennies on the dollar in bankruptcy court, and even still that would be a questionable use of resources.
And that makes no strategic sense at all, given how similar sport and surgibot are (single port) and how far behind sport is in terms of design freeze, verification and validation, efficacy tests.
While TRXC's $60M in cash may seem like a lot of $$ to Titan investors, it's just a drop in the bucket when you're pursuing the regulatory approval and commercialization of two surgical robots.
I would just say, and this seems to get lost among investors and skeptics, surgibot is not dead. Surgibot is not a drug that failed its phase III trial and has no options going forward. This is a medical device and it does not require a redesign. Trxc has met with the FDA in person three times since the surgibot rejection and they are clearing a path forward for eventual approval of surgibot in 2017.
Recall that in 1999 the FDA rejected 510(k) approval of the Da Vinci system, and approved it 7 months later after they met with ISRG multiple times and hashed out the fine details.
I will be giving Todd Pope an earful if he buys Titan. What a stupid move on their part if they did that. Titan is desperate, they need a white knight to come in and save them. Medtronic is working on the 10th iteration/prototype of their surgical robot. JNJ is working on their own prototype (I have spoken with a surgeon who has tested it out, but no one on ihub board believes me because they are enamored with the idea that jnj is only working on an open platform and will be that white knight for Titan), perhaps Stryker or Smith and Nephew is a possible candidate to buy out Titan.
Market Data 
Markets 
AI
